Boothbay Fund Management, LLC Autolus Therapeutics PLC Transaction History

Boothbay Fund Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$2.32 - $3.36 $6,048 - $8,759	2,607 Added 9.58%	29,822 $69,000
Q3 2022 Nov 14, 2022	SELL	$2.04 - $3.76 $10,124 - $18,660	-4,963 Reduced 15.42%	27,215 $58,000
Q2 2022 Aug 15, 2022	SELL	$2.04 - $4.68 $10,185 - $23,367	-4,993 Reduced 13.43%	32,178 $91,000
Q1 2022 May 16, 2022	SELL	$3.52 - $5.46 $70,301 - $109,047	-19,972 Reduced 34.95%	37,171 $155,000
Q4 2021 Feb 14, 2022	SELL	$5.1 - $7.0 $200,333 - $274,967	-39,281 Reduced 40.74%	57,143 $297,000
Q3 2021 Nov 15, 2021	SELL	$5.32 - $7.37 $507,506 - $703,068	-95,396 Reduced 49.73%	96,424 $632,000
Q2 2021 Aug 16, 2021	BUY	$4.78 - $7.96 $200,320 - $333,587	41,908 Added 27.96%	191,820 $1.27 Million
Q1 2021 May 17, 2021	BUY	$5.49 - $9.36 $823,016 - $1.4 Million	149,912 New	149,912 $859,000
Q1 2019 May 15, 2019	SELL	$24.38 - $34.71 $195,040 - $277,680	-8,000 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$24.21 - $48.01 $193,680 - $384,080	8,000 New	8,000 $263,000

104

163M

2.8K

13.4K

Ticker AUTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,909,800
Market Cap $208M
Description
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...

Get notified when there are updates to the investment portfolio of Boothbay Fund Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Boothbay Fund Management, LLC with notifications on news.